» Articles » PMID: 37958985

Vasculoprotective Potential of Baicalein in Angiotensin II-Infused Abdominal Aortic Aneurysms Through Inhibiting Inflammation and Oxidative Stress

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Nov 14
PMID 37958985
Authors
Affiliations
Soon will be listed here.
Abstract

Aortic wall inflammation, abnormal oxidative stress and progressive degradation of extracellular matrix proteins are the main characteristics of abdominal aortic aneurysms (AAAs). The nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome dysregulation plays a crucial role in aortic damage and disease progression. The first aim of this study was to examine the effect of baicalein (5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one) on AAA formation in apolipoprotein E-deficient (ApoE) mice. The second aim was to define whether baicalein attenuates aberrant vascular smooth muscle cell (VSMC) proliferation and inflammation in VSMC culture. For male ApoE mice, a clinically relevant AAA model was randomly divided into four groups: saline infusion, baicalein intraperitoneal injection, Angiotensin II (Ang II) infusion and Ang II + baicalein. Twenty-seven days of treatment with baicalein markedly decreased Ang II-infused AAA incidence and aortic diameter, reduced collagen-fiber formation, preserved elastic structure and density and prevented smooth muscle cell contractile protein degradation. Baicalein inhibited rat VSMC proliferation and migration following the stimulation of VSMC cultures with Ang II while blocking the Ang II-inducible cell cycle progression from G/G to the S phase in the synchronized cells. Cal-520 AM staining showed that baicalein decreased cellular calcium in Ang II-induced VSMCs; furthermore, a Western blot assay indicated that baicalein inhibited the expression of PCNA and significantly lowered levels of phospho-Akt and phospho-ERK, along with an increase in baicalein concentration in Ang II-induced VSMCs. Immunofluorescence staining showed that baicalein pretreatment reduced NF-κB nuclear translocation in Ang II-induced VSMCs and furthered the protein expressions of NLRP3 while ASC and caspase-1 were suppressed in a dose-dependent manner. Baicalein pretreatment upregulated Nrf2/HO-1 signaling in Ang II-induced VSMCs. Thus, 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) staining showed that its reactive oxygen species (ROS) production decreased, along with the baicalein pretreatment. Our overall results indicate that baicalein could have therapeutic potential in preventing aneurysm development.

Citing Articles

Fosinopril inhibits Ang II-induced VSMC proliferation, phenotype transformation, migration, and oxidative stress through the TGF-β1/Smad signaling pathway.

Chen S, Ye L Open Life Sci. 2024; 19(1):20220955.

PMID: 39588111 PMC: 11588003. DOI: 10.1515/biol-2022-0955.

References
1.
Ma G, Liu C, Wei B, Qiao J, Lu T, Wei H . Baicalein inhibits DMBA/TPA-induced skin tumorigenesis in mice by modulating proliferation, apoptosis, and inflammation. Inflammation. 2012; 36(2):457-67. DOI: 10.1007/s10753-012-9566-y. View

2.
Michel J, Martin-Ventura J, Egido J, Sakalihasan N, Treska V, Lindholt J . Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res. 2010; 90(1):18-27. PMC: 3058728. DOI: 10.1093/cvr/cvq337. View

3.
Golledge J, Tsao P, Dalman R, Norman P . Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008; 118(23):2382-92. PMC: 2752737. DOI: 10.1161/CIRCULATIONAHA.108.802074. View

4.
Karasaki K, Kokubo H, Bumdelger B, Kaji N, Sakai C, Ishida M . Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin-Deficient Mice via Upregulation of Angiotensin (1-7). J Am Heart Assoc. 2023; 12(3):e027589. PMC: 9973615. DOI: 10.1161/JAHA.122.027589. View

5.
Golledge J, van Bockxmeer F, Jamrozik K, McCann M, Norman P . Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol. 2010; 105(10):1480-4. DOI: 10.1016/j.amjcard.2009.12.076. View